Clinical features and outcome of multisystem inflammatory syndrome in children (MIS-C) patients in northwest general hospital and research center Peshawar
DOI:
https://doi.org/10.59736/IJP.23.04.1037Keywords:
Hyperinflammation, Inflammatory Syndrome, SARS-CoV-2Abstract
Background: Multisystem Inflammatory Syndrome in Children (MIS-C) is a post–COVID-19 hyperinflammatory condition with multisystem involvement. Due to limited regional data, this study assessed the clinical features and outcomes of MIS-C in children admitted to Northwest General Hospital, Peshawar.
Methods: A six-month descriptive cross-sectional study was conducted after ethical approval. Seventy-nine patients aged 0–19 years meeting WHO/CDC MIS-C criteria were included through sequential sampling. Clinical presentation, laboratory findings, treatment, and outcomes were recorded and analyzed using SPSS 23. Results were reported as frequencies, percentages, and means where appropriate.
Results: Most patients were 6–12 years old (44.3%) and female (63.3%). Prior COVID-19 exposure was documented in 69.6%, and 72.2% had elevated antibody titers. Common symptoms were reduced oral intake (59.5%), rash (45.6%), conjunctival congestion (40.5%), vomiting (40.5%), abdominal pain (29.1%), hypotension (35.4%), and tachycardia (32.9%). CRP (74.7%), ESR (49.4%), and AST (51.9%) were the most frequently elevated markers. Cardiac dysfunction occurred in 7.6% of cases. Intravenous immunoglobulins (IVIG, 94.9%) and steroids (72.2%) were the main treatments; 36.7% required inotropes and 3.8% mechanical ventilation. Mortality was 21.5%, significantly higher among those with concurrent measles.
Conclusion: MIS-C commonly involved gastrointestinal, cardiovascular, and mucocutaneous systems. Most children improved with timely Intravenous immunoglobulins, steroid therapy, and supportive care, but coexisting measles was associated with markedly poorer outcomes
References
Hopkins J. COVID-19 map – Johns Hopkins Coronavirus Resource Center [Internet]. Baltimore (MD): Johns Hopkins University; 2020 [cited 2025 Mar 8]. Available from: https://coronavirus.jhu.edu/map.html
Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuffreda M, et al. An outbreak of severe Kawasaki-like disease at the Italian epicenter of the SARS-CoV-2 epidemic: An observational cohort study. Lancet 2020; 395:1771-8.
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395:1033-4.
Henderson LA, Canna SW, Schulert GS, Volpi S, Lee PY, Kernan KF, et al. On the alert for cytokine storm: Immunopathology in COVID-19. Arthritis Rheumatol 2020; 72:1059-63.
Liu L, Wei Q, Lin Q, Fang J, Wang H, Kwok H, et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight 2019; 4:123158
Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MB, et al. Multisystem inflammatory syndrome in US. Children and adolescents. N Engl J Med 2020; 383:334-46.
Whittaker E, Bamford A, Kenny J, Kaforou M, Jones CE, Shah P, et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA 2020; 324:259-69
Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 2020; 395:1607-8
Godfred-Cato S, Bryant B, Leung J, Oster ME, Conklin L, Abrams J, et al. COVID-19-associated multisystem inflammatory syndrome in children – United States, March-July 2020. MMWR Morb Mortal Wkly Rep 2020; 69:1074-80.
Ben-Shimol S, Livni G, Megged O, Greenberg D, Danino D, Youngster I, et al. COVID-19 in a subset of hospitalized children in Israel. J Pediatric Infect Dis Soc 2021; 10:757-65.
Ghatasheh G, Al Dhanhani H, Goyal A, Noureddin MB, Al Awaad D, Peerwani Z. COVID-19-related giant coronary aneurysms in an infant with multisystem inflammatory disorder in children: The first case report from the United Arab Emirates and the Arab Region. Case Rep Infect Dis 2021; 2021:8872412
Lima-Setta F, Magalhães-Barbosa MC, Rodrigues-Santos G, Figueiredo EA, Jacques ML, Zeitel RS, et al. Multisystem inflammatory syndrome in children (MIS-C) during SARS-CoV-2 pandemic in Brazil: A multicenter, prospective cohort study. J Pediatr (Rio J) 2021; 97:354-61.
Bar-Meir M, Guri A, Godfrey ME, Shack AR, Hashkes PJ, Goldzweig O, et al. Characterizing the differences between multisystem inflammatory syndrome in children and Kawasaki disease. Sci Rep 2021; 11:13840.
Hoste L, Van Paemel R, Haerynck F (2021) Multisystem infammatory syn - drome in children related to COVID-19: a systematic review. Eur J Pediatr 180:2019–2034
Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK, Bassiri H, et al. American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: Version 1. Arthritis Rheumatol 2020; 72:1791-805
Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK, Bassiri H, et al. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2. Arthritis Rheumatol Hoboken NJ. 2021 Apr;73(4): e13–29.
Williams V, Dash N, Suthar R, Mohandoss V, Jaiswal N, Kavitha TK, et al. Clinico laboratory profile, treatment, intensive care needs, and outcome of pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2: a systematic review and meta-analysis. J Pediatr Intensive Care. 2020 Nov 19;11(1):1-12. doi: 10.1055/s-0040-1719173.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Fatima Rehman, Bilal Sethi, Saima Noreen, Saba Hussain, Aziz Ur Rehman
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purpose. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
